Global Biodefense Market Growth (Status and Outlook) 2023-2029

Global Biodefense Market Growth (Status and Outlook) 2023-2029

Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.

In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.
LPI (LP Information)' newest research report, the “Biodefense Industry Forecast” looks at past sales and reviews total world Biodefense sales in 2022, providing a comprehensive analysis by region and market sector of projected Biodefense sales for 2023 through 2029. With Biodefense sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biodefense industry.
This Insight Report provides a comprehensive analysis of the global Biodefense landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biodefense portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biodefense market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biodefense and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biodefense.
The global Biodefense market size is projected to grow from US$ 1119.1 million in 2022 to US$ 1865.5 million in 2029; it is expected to grow at a CAGR of 7.6% from 2023 to 2029.
The major players in global Biodefense market include Emergent Biosolutions, Hytest, GSK, etc. The top 3 players occupy about 60% shares of the global market. North America, Europe and Asia are key Regions of Sales. Anthrax and Smallpox are main types, with a share about 70%. US Civilian Market is the main application, which holds a share about 55%.
This report presents a comprehensive overview, market shares, and growth opportunities of Biodefense market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Anthrax
Smallpox
Botulism
Radiation/Nuclear
Others
Segmentation by application
US Military Market
US Civilian Market
Non - US Market
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Emergent Biosolutions
Hytest
GSK
Sanofi
PharmAthene
Bavarian Nordic
SIGA Technologies
Arbutus Biopharma
DynPort Vaccine
Xoma Corporation
Ichor Medical Systems
Aeolus Pharmaceuticals
Achaogen
Elusys Therapeutics
Dynavax Technologies
Cleveland BioLabs
Soligenix
Alnylam Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.